Exclusive collaboration and license agreement focuses on advancing novel, T cell therapy “Seed-and-Boost” approach exploiting the mechanism of the CUE-100 series of Immuno-STATs® Novel therapeutic approach is designed to enable in vivo expansion and activation of...
If you are headed to BioCentury Inc.’s BioEquity Europe Conference and are interested in learning how ImmunoScape is working toward the development of TCR-based therapies against solid tumors, send us a message. Our Co-founder and VP of Innovation Michael...
Next-gen TCR-based therapies against solid tumors have the power to disrupt and transform the development, delivery, and efficacy for cancer patients. Dan Macleod, ImmunoScape’s SVP of Discovery, will be an expert speaker at this year’s TCR-based Therapies for Solid...
